CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
MN-001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02503657
NCT02503657Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

MediciNova·interventional·Posted Jul 21, 2015·Updated Jan 23, 2026

In Brief

A Phase 2 clinical trial evaluating MN-001 and Placebo for Idiopathic Pulmonary Fibrosis and IPF. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This is a randomized, placebo-controlled, double-blind, 6-month study followed by a 6-month open-label extension phase to evaluate the efficacy, safety, and tolerability of MN-001 in patients diagnosed with moderate to severe idiopathic pulmonary fibrosis (IPF). Participants were randomly assigned to receive MN-001 or matching placebo twice daily over a 26-week period. A total of 15 participants were enrolled.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis, IPF
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 21, 2015
Enrollment StartMar 9, 2016
Primary CompletionDec 7, 2020
Study CompletionMar 15, 2022
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.9 years ago

Interventions

MN-001drug

A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity

Placebodrug

Excipients of MN-001/tipelukast